GLP-1 drug demand rising, but not all packaged foods companies in the crosshairs

  • 📰 Investingcom
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 53%

Business News News

Business Business Latest News,Business Business Headlines

GLP-1 drug demand rising, but not all packaged foods companies in the crosshairs

Investing.com -- As signs emerge that demand for GLP-1 drugs is stronger than expected, many are fearing the worst for packaged-food companies, but Bernstein believes that some companies are likely to fare better than others as patients on these weight-loss drugs shift appetite in favor of more protein-based foods.

While official data from IQVIA suggests only about 1.4% of U.S. adults are currently taking branded GLP-1 drugs like Ozempic and Wegovy, there are signs that demand is stronger than expected/ This discrepancy between the survey and IQVIA data point to a potentially larger market for compounded GLP-1 drugs than previously thought.

While the signs of increased demand are expected to dent appetite for packaged foods, Bernstein believes that some companies such as) from Market-Perform to Outperform, and its price target raised from $55 to $58 as evidence shows that GLP-1 users favor more protein rich foods and beverages.), however, was downgraded from Outperform to Market-Perform and its target price cut from $230 to $205 on worries volume recovery will struggle as GLP-1 demand appears to be on the up and up.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 450. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

JPMorgan says this new player in the GLP-1 market could rally 45%This GLP-1 drug could emerge as the next big treatment and rival key competitors.
Source: CNBC - 🏆 12. / 72 Read more »